Dovato is manufactured by ViiV Healthcare [1]. ViiV Healthcare is a global specialist HIV company established in 2009 by GlaxoSmithKline (GSK) and Pfizer, with Shionogi later joining in 2012 [1].
What is Dovato used for?
Dovato is a prescription medication used to treat human immunodeficiency virus type 1 (HIV-1) infection in adults and children who weigh at least 25 kg (55 lbs) [2]. It is indicated as a complete regimen for the treatment of HIV-1 in certain individuals [2].
How does Dovato work?
Dovato is a two-drug combination consisting of dolutegravir and lamivudine [2]. Dolutegravir is an integrase strand transfer inhibitor (INSTI), and lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) [2]. Together, these medications work by preventing HIV from multiplying [2].
When does Dovato's patent expire?
Information regarding the specific patent expiry dates for Dovato is available through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods [3].
What are the alternatives to Dovato?
Other HIV treatment options include various single-agent medications or combination therapies that may include different classes of antiretroviral drugs. The choice of treatment depends on individual patient factors, including viral load, CD4 count, and potential drug resistance [4].
Who are ViiV Healthcare's competitors in HIV treatment?
ViiV Healthcare competes with other pharmaceutical companies that develop and market HIV medications. Major competitors include Gilead Sciences, Merck & Co., and AbbVie, among others, all of which offer a range of antiretroviral therapies [5].
What clinical data supports Dovato's efficacy?
Dovato's efficacy has been demonstrated in clinical trials, such as the pivotal DOVATO (dolutegravir/lamivudine) Phase 3 trial, which showed non-inferiority compared to dolutegravir plus tenofovir disoproxil fumarate/emtricitabine in virologically suppressed adults with HIV-1 [6].
What are potential side effects of Dovato?
Common side effects reported with Dovato include upper respiratory tract infection, headache, and diarrhea [2]. Serious side effects can occur, and individuals should discuss potential risks with their healthcare provider [2].
How is Dovato regulated?
Dovato is regulated by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These agencies review clinical trial data to determine the safety and efficacy of the drug before approving it for market [7].
---
Sources:
[1] ViiV Healthcare. (n.d.). About ViiV Healthcare. https://www.viivhealthcare.com/about-viiv-healthcare/
[2] Dovato Prescribing Information. (n.d.). https://www.gsksource.com/Downloads/Dovato_PI.pdf
[3] DrugPatentWatch.com. (n.d.). *Dovato*. https://www.drugpatentwatch.com/
[4] U.S. Department of Health and Human Services. (n.d.). *HIV Treatment Guidelines*. https://clinicalinfo.hiv.gov/en/guidelines
[5] Pharmaceutical Technology. (n.d.). *Top 10 pharmaceutical companies in the HIV market*. https://www.pharmaceutical-technology.com/features/top-hiv-companies/
[6] ViiV Healthcare. (2019, July 24). *ViiV Healthcare announces FDA approval of Dovato (dolutegravir/lamivudine) tablets, the first 2-drug regimen for HIV treatment*. https://www.viivhealthcare.com/media/press-releases/2019/viiv-healthcare-announces-fda-approval-of-dovato-dolutegravir-lamivudine-tablets-the-first-2-drug-regimen-for-hiv-treatment/
[7] European Medicines Agency. (n.d.). *About the European Medicines Agency*. https://www.ema.europa.eu/en/about-ema